Takeda’s TAK-755 shows potential in Phase 3 trial for cTTP prophylaxis
Takeda Pharmaceutical Company has revealed promising interim results from its global Phase 3 trial of TAK-755, a recombinant ADAMTS13 protein in development for the prophylactic ... Read More